New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 13, 2024 - Galderma announced the FDA approval of Nemluvio (nemolizumab-ilto), for the treatment of adults with prurigo nodularis.
Download PDF
Return to publications
